Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's…
First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBMPart B expected…
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company…
NEW YORK, Aug. 14, 2024 /PRNewswire/ -- The global chromatography market size is estimated to grow by USD 3.99 billion…
Protocol digitization extracts structured data elements from unstructured textAutomates database study builds, reducing build timelines by up to 30%Deployed within…
Companies share joint commitment to leveraging technology for STEM educationAccessible education on cutting-edge science and technology represents critical step toward…
Company reviews goals and significance of the study and outlines development strategy in Mild Cognitive Impairment due to Alzheimer’s diseaseROCHESTER,…
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:…
Expects to report topline results in 2025 from Phase 2a influenza A human challenge study with oral CC-42344, including initial…
MARLBOROUGH, Mass., Aug. 13, 2024 /PRNewswire/ -- Quantiphi, an award-winning AI-first digital engineering company today announced it has acquired a…